In a report released today, Soumit Roy from JonesTrading reiterated a Buy rating on Deciphera Pharmaceuticals Inc (DCPH), with a price target of $65. The company’s shares opened today at $22.58.
According to TipRanks.com, Roy is ranked 0 out of 5 stars with an average return of -22.5% and a 17.0% success rate. Roy covers the Healthcare sector, focusing on stocks such as Neon Therapeutics Inc, Surface Oncology Inc, and Mirati Therapeutics.
Currently, the analyst consensus on Deciphera Pharmaceuticals Inc is a Strong Buy with an average price target of $54, a 139.1% upside from current levels. In a report issued on July 18, Deutsche Bank also initiated coverage with a Buy rating on the stock with a $42 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $41 and a one-year low of $18.55. Currently, Deciphera Pharmaceuticals Inc has an average volume of 245.2K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Deciphera Pharmaceuticals, Inc. operates as a biotechnology company which develops and manufactures kinase inhibitor treatments for cancer by cutting off the ability of tumor cells to thrive and spread. The company designs a drug candidate, DCC-2618, to inhibit the full spectrum of mutant or amplified KIT and PDGFRa kinases that drive cancers such as gastrointestinal stromal tumors (GIST), advanced systemic mastocytosis (ASM), gliomas, and other solid tumors. It also develops two other clinical-stage drug candidates, DCC-3014 and rebastinib, as immuno-oncology kinase, inhibitors targeting the kinases CSF1R, and TIE2 kinas. The company was founded by Peter A. Petillo and Daniel L. Flynn in November 2003 and is headquartered in Waltham, MA.